Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10618479rdf:typepubmed:Citationlld:pubmed
pubmed-article:10618479lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0227525lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C1510411lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0001455lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:10618479lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:10618479pubmed:issue2-3lld:pubmed
pubmed-article:10618479pubmed:dateCreated2000-2-29lld:pubmed
pubmed-article:10618479pubmed:abstractTextWe investigated the mechanisms of transforming growth factor-beta1 (TGF-beta1) inhibition on transforming growth factor-alpha (TGF-alpha)-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes. TGF-alpha (1.0 ng/ml) produced a 4.2-fold elevation of DNA synthesis during 3 h of culture and a 1. 2-fold increase in nucleus number (proliferation) during 4 h of culture. TGF-beta1 dose dependently inhibited the TGF-alpha-induced hepatocyte DNA synthesis and proliferation: half-maximal inhibition occurred at a TGF-beta1 concentration of 0.08 ng/ml. The inhibitory effects of 1.0 ng/ml TGF-beta1 were almost completely reversed by adenylate cyclase inhibitors, 2,4-dideoxyadenosine (10(-6) M), and somatostatin (3 x 10(-7) M), or by a specific inhibitor of protein kinase A, H-89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride; 10(-7) M). In addition, while TGF-alpha did not affect the basal cellular adenosine 3',5'-monophosphate (cAMP) levels, TGF-beta1 was found to produce dose-dependent increases in cellular cAMP levels. The cAMP-elevating effects of TGF-beta1 were also reversed by 2,4-dideoxyadenosine (10(-6) M), and somatostatin (3 x 10(-7) M), but not by H-89 (10(-7) M). The present results suggest that the specific mechanisms involved in the growth inhibitory effect of TGF-beta1 on TGF-alpha-induced hepatocyte DNA synthesis and proliferation are via stimulation of adenylate cyclase, which increases intracellular cAMP and subsequently activates protein kinase A.lld:pubmed
pubmed-article:10618479pubmed:languageenglld:pubmed
pubmed-article:10618479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:citationSubsetIMlld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10618479pubmed:statusMEDLINElld:pubmed
pubmed-article:10618479pubmed:monthDeclld:pubmed
pubmed-article:10618479pubmed:issn0014-2999lld:pubmed
pubmed-article:10618479pubmed:authorpubmed-author:KimuraMMlld:pubmed
pubmed-article:10618479pubmed:authorpubmed-author:OgiharaMMlld:pubmed
pubmed-article:10618479pubmed:issnTypePrintlld:pubmed
pubmed-article:10618479pubmed:day15lld:pubmed
pubmed-article:10618479pubmed:volume386lld:pubmed
pubmed-article:10618479pubmed:ownerNLMlld:pubmed
pubmed-article:10618479pubmed:authorsCompleteYlld:pubmed
pubmed-article:10618479pubmed:pagination271-7lld:pubmed
pubmed-article:10618479pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:meshHeadingpubmed-meshheading:10618479...lld:pubmed
pubmed-article:10618479pubmed:year1999lld:pubmed
pubmed-article:10618479pubmed:articleTitleTransforming growth factor-beta1 inhibits the growth of primary adult rat hepatocyte cultures by increasing cAMP levels.lld:pubmed
pubmed-article:10618479pubmed:affiliationDepartment of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Josai University, 1-1, Keyakidai, Sakado City, Japan.lld:pubmed
pubmed-article:10618479pubmed:publicationTypeJournal Articlelld:pubmed